Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy.
Conclusions: Dose escalation to MRSI-defined DIL is feasible. Toxicity was low but incompletely assessed due to limited patients' enrollment.
PMID: 30038638 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Colorectal Cancer | External Beam Therapy | Gastroenterology | Prostate Cancer | Radiation Therapy | Study | Toxicology